183 related articles for article (PubMed ID: 28821265)
1. Poncet's disease after the intravesical instillation of Bacillus Calmette-Guérin (BCG): a case report.
Sampaio PCM; Lira YG; Ribeiro HYU; de Paula Moreira F; Gadelha MSM; da Cruz SFS
BMC Res Notes; 2017 Aug; 10(1):416. PubMed ID: 28821265
[TBL] [Abstract][Full Text] [Related]
2. [Acute reactive arthritis after intravesical instillation of bacillus Calmette-Guérin. Two case reports and literature review].
Miranda S; Verdet M; Héron F; Vittecoq O; Levesque H; Marie I
Rev Med Interne; 2010 Aug; 31(8):558-61. PubMed ID: 20494494
[TBL] [Abstract][Full Text] [Related]
3. Reactive arthritis following treatment with intravesical Bacillus Calmette-Guerin for papillary carcinoma of bladder.
Singh YP; Roy D; Jois B; Shetti M
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35418381
[TBL] [Abstract][Full Text] [Related]
4. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.
Pérez-Jacoiste Asín MA; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Tejido Á; San Juan R; Arrebola-Pajares A; Lizasoain M; Prieto S; Aguado JM
Medicine (Baltimore); 2014 Oct; 93(17):236-254. PubMed ID: 25398060
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
Shepherd AR; Shepherd E; Brook NR
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
[TBL] [Abstract][Full Text] [Related]
6. Sequential bacillus Calmette-Guérin/Electromotive Drug Administration of Mitomycin C as the Standard Intravesical Regimen in High Risk Nonmuscle Invasive Bladder Cancer: 2-Year Outcomes.
Gan C; Amery S; Chatterton K; Khan MS; Thomas K; O'Brien T
J Urol; 2016 Jun; 195(6):1697-703. PubMed ID: 26845426
[TBL] [Abstract][Full Text] [Related]
7. Single immediate instillation of chemotherapy is associated with decreased recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer who receive adjuvant induction bacillus Calmette-Guérin therapy.
Fujita N; Hatakeyama S; Momota M; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Int J Urol; 2022 Aug; 29(8):867-875. PubMed ID: 35577361
[TBL] [Abstract][Full Text] [Related]
8. Reiter's syndrome postintravesical Bacillus Calmette-Guérin instillations.
Ng KL; Chua CB
Asian J Surg; 2017 Apr; 40(2):163-165. PubMed ID: 25183290
[TBL] [Abstract][Full Text] [Related]
9. Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer.
Yokomizo A; Kanimoto Y; Okamura T; Ozono S; Koga H; Iwamura M; Tanaka H; Takahashi S; Tsushima T; Kanayama HO; Akaza H; Shinohara N; Mugiya S; Nomata K; Nakamura T; Naito S
J Urol; 2016 Jan; 195(1):41-6. PubMed ID: 26307162
[TBL] [Abstract][Full Text] [Related]
10. Reactive arthritis after the intravesical instillation of BCG.
Macía Villa C; Sifuentes Giraldo W; Boteanu A; González Lanza M; Bachiller Corral J
Reumatol Clin; 2012; 8(5):284-6. PubMed ID: 22377450
[TBL] [Abstract][Full Text] [Related]
11. A case series and review of Poncet's disease, and the utility of current diagnostic criteria.
Sharma A; Pinto B; Dogra S; Sharma K; Goyal P; Sagar V; Dhir V; Sharma S; Singh S
Int J Rheum Dis; 2016 Oct; 19(10):1010-1017. PubMed ID: 26354099
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder.
Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM;
Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729
[TBL] [Abstract][Full Text] [Related]
13. Refractory arthropathy after intravesical bacillus Calmette-Guérin therapy. Usefulness of isoniazide.
Milas L; Maillefert JF; Michel F; Piroth C; Wautot A; Tavernier C
Rev Rhum Engl Ed; 1999 Feb; 66(2):106-8. PubMed ID: 10084171
[TBL] [Abstract][Full Text] [Related]
14. Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study.
Hsu CW; Chiu YC; Hu HY; Fan YH; Hong SC; Cheng WM
BMC Urol; 2020 Jul; 20(1):91. PubMed ID: 32641099
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
[TBL] [Abstract][Full Text] [Related]
16. A rare case of multi-focal human TB after BCG instillation for non-muscle-invasive bladder cancer.
Riccardi N; Ferrarese M; Castellotti P; Mazzola E; Sozzi F; Rigatti P; Vanzulli A; Sotgiu G; Codecasa L
Urologia; 2020 Nov; 87(4):199-202. PubMed ID: 31271544
[TBL] [Abstract][Full Text] [Related]
17. [A Case Diagnosed as Iatrogenic Vesical Tuberculosis 4 Years after Intravesical Immunotherapy Using Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Carcinoma].
Kudo T; Iwasa N; Maeda S; Mitarai S
Kansenshogaku Zasshi; 2016 Nov; 90(6):809-13. PubMed ID: 30277373
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune disorders caused by intravesical bacillus Calmette-Guerine treatment: A systematic review.
Anis O; Yogev D; Dotan A; Tsur AM; David P; Vishnevskia Dai V; Laufer M; Dotan Z; Shoenfeld Y
Autoimmun Rev; 2023 Jun; 22(6):103329. PubMed ID: 37061015
[TBL] [Abstract][Full Text] [Related]
19. The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin therapy.
Kikuchi H; Abe T; Miyake M; Miyata H; Matsumoto R; Osawa T; Nishimura N; Fujimoto K; Inokuchi J; Yoneyama T; Tomida R; Numakura K; Matsushita Y; Matsumoto K; Sato T; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Shinohara N
Jpn J Clin Oncol; 2024 Feb; 54(2):192-200. PubMed ID: 37974430
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
